[logo] HealthTree Foundation
search more_vert
close
person Sign In / Create Account

Frederick Locke, MD

DLBCL Specialist

location_city Moffitt Cancer Center

Specialities: Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma

Spoken languages: English

Clinical Expertise

  • Diffuse Large B Cell Lymphoma
  • Non-Hodgkin Lymphoma
  • Hodgkin Lymphoma

About

Dr. Locke is a medical oncologist and translational researcher in the Department of Blood and Marrow Transplant and Cellular Immunotherapy. He leads the Immune Cell Therapy (ICE-T) initiative at Moffitt, an integrated cross-departmental translational team. Dr. Locke is a clinical research leader in the field of Chimeric Antigen Receptor (CAR) T cell therapy, acting as a national P.I. for several pivotal trials of anti-CD19 CARs for lymphoma. In addition, Dr. Locke is translating findings from his laboratory into new cellular immunotherapies such as the Moffitt created whole protein survivin tumor vaccine for multiple myeloma. Dr. Locke graduated with a B.S. in Physiology from Michigan State University, and with an M.D. from Wayne State University. He stayed at Wayne State and the Detroit Medical Center for Internal Medicine residency training and then served as Chief Medical Resident at Detroit Receiving. Dr. Locke received Medical Oncology, clinical research, and laboratory research training at the University of Chicago.  Dr. Locke provides care for multiple myeloma, lymphoma, and leukemia patients. He oversees both autologous and allogeneic hematopoietic stem cell transplants as well as cellular immunotherapy treatments such as CAR T cell Therapy.

Location

Moffitt Cancer Center: 12903 USF Magnolia Drive, Tampa, FL 33612, USA

newsletter icon

Get the latest thought leadership on your Waldenström's Macroglobulinemia delivered straight to your inbox

Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.